Search Results - xinhua+ji

7 Results Sort By:
CD206 Small Molecule Modulators, Their Use and Methods for Preparation
Abstract: Pancreatic ductal adenocarcinoma (PDA) accounts for more than 90% of pancreatic cancer cases, and it is one of the most aggressive malignancies with a 5-year survival rate of 6%. The high mortality rate caused by PDA is primarily from the lack of early diagnosis – it is often asymptomatic in early stages – and a poor response to conventional...
Published: 4/8/2024   |   Inventor(s): Udo Rudloff, Juan Marugan, Xin Hu, Raul Calvo, Noel Southall, Bolormaa Baljinnyam
Keywords(s): CD206, M1 Macrophage, M2 Macrophage, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDA, Rudloff, TAM, Tumor-Associated Macrophages
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
Novel HPPK (Bacterial Protein) Inhibitors for Use as Antibacterial Agents
Abstract: Research and development leading to the discovery of novel antibiotics has waned in recent years. At the same time, the emergence and spread of antimicrobial resistance has compounded the global danger to human health from bacterial infections.  The bacterial protein 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK) is a key enzyme...
Published: 4/8/2024   |   Inventor(s): Xinhua Ji, Genbin Shi, Gary Shaw
Keywords(s): ANTIBIOTIC, Bacterial Protein, BACTERICIDAL, Biodefense, Broad Spectrum, Folate Biosynthesis, HPPK, Ji, small molecule
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Therapeutics
PARP Inhibitor and NO-Donor Dual Prodrugs as Anticancer Agents
Abstract: Poly-ADP ribose polymerase-1 (PARP-1) is a critical enzyme involved in DNA repair.  The inhibition of PARP has emerged as a promising strategy in cancer therapy.  Numerous PARP inhibitors have been developed and advanced into clinical trials, both for use as single agents in specific patient populations and as combination therapies with various...
Published: 5/22/2024   |   Inventor(s): Anna Maciag, Joseph Saavedra, Larry Keefer, Xinhua Ji, Vandana Kumari
Keywords(s): nitric oxide, PARP, poly-ADP-ribose polymerase, prodrug
Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing
The Use of Emetine for the Treatment of SARS-CoV-2 Infection
This technology includes the clinical use of the small compound emetine for the treatment of SARS-CoV-2. Previous work has shown that emetine has antiviral properties against some DNA and RNA viruses. It is thought that the mechanism may involve blocking protein synthesis. Work has shown that emetine has potential antiviral activity in multiple tissues...
Published: 10/28/2024   |   Inventor(s): Mark Henderson, Juan Marugan, Andreas Dulcey Garcia, Xin Hu, Marc Ferrer-Alegre, Noel Southall
Keywords(s): Emetine, Infection, SARS-CoV-2, treatment, VLXXXX, WIXXXX, WKXXXX
Category(s): TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Research Materials
Creation of a High-density Screening Format and the Identification of Small Molecule Inhibitors of the SIX/EYA Interaction for the Treatment of Cancers
The technology includes the creation of a high-throughput assay and the identification and use of small molecules that inhibit the SIX/EYA interaction as a treatment for cancer. The Eya proteins are phosphatases that form a complex and are activated by the Six family of homeobox transcription factors. The interaction of Eya and Six mediates breast cancer...
Published: 10/28/2024   |   Inventor(s): Marc Ferrer-Alegre, Xin Hu, Juan Marugan, Lesley Mathews, Heide Ford, Melanie Blevins, Rebecca Mull, Rui Zhao
Keywords(s): cancers, Identification, Identifying, Inhibitors, INTERACTION, Listed LPM Vathyam as of 4/15/2015, Method, MOLECULE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SIX/EYA, Small, treatment, VCXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): Application > Research Materials, Application > Therapeutics, TherapeuticArea > Oncology
Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction
This technology includes a chemical series, including the NCGC00538279 compound, that selectively activates the GHSR1a G-protein pathway for calcium mobilization while only partially activating the beta-arrestin-2 translocation pathway. The resulting chemical series may be therapeutically valuable for addictive disorders. Activation of the GHSR1a G-protein...
Published: 10/28/2024   |   Inventor(s): Noel Southall, Marc Ferrer-Alegre, Daniel Jansen, Mark Henderson, Xin Hu, David Kim, Juan Marugan
Keywords(s): ADDICTION, Chemical, FOOD, Funtionally, Ghrelin, LIGAND, NCG00538279, Novel, RECEPTOR, SELECTIVE, treatment, VEXXXX, VGXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): TherapeuticArea > Neurology, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Research Materials
Heterocyclic Compounds for the Treatment of Hepatitis C Virus
The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that have changed the HCV treatment paradigm. However, the...
Published: 10/28/2024   |   Inventor(s): Zongyi Hu, Juan Marugan, Noel Southall, Xin Hu, Jingbo Xiao, Shanshan (Melissa) He, Marc Ferrer-Alegre, Wei Zheng, Kevin Frankowski, Frank Schoenen, Kelin Li, Tsanyang (Jake) Liang
Keywords(s): C, Class, compounds, DB4BXX, Development, Hepatitis, Novel, treatment, VLXXXX, WKXXXX, YAXXXX, YBXXXX
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease